|
**Overview**: Spinocerebellar Ataxia 17 (SCA-17) Mutation Panel**Introduction**: The Spinocerebellar Ataxia 17 (SCA-17) Mutation Panel is a diagnostic tool designed to screen for SCA-17 using whole blood samples. In India, SCA-17 (CAG expansion in TBP gene) is rare but reported, presenting with ataxia, chorea, psychiatric symptoms, and dementia (often Huntington-like), with variable penetrance. High morbidity from underdiagnosis in rural/low-SES families with progressive neurological decline, limited genetic testing, delayed symptomatic management or counseling leading to disability or misdiagnosis as psychiatric disorder. Per neurology practices aligned with ICMR and Indian Academy of Neurology guidelines, the test employs PCR for TBP gene mutation and CAG repeats over 1-2 days with high accuracy, valuable for confirming diagnosis and repeat sizing. This diagnostic falls under genetic disorder screening and targets patients with ataxia + chorea/psychiatric features or family history, addressing accurate detection to guide supportive care and family planning. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise molecular confirmation and reducing diagnostic odyssey. Its whole blood-based approach ensures reliable repeat expansion detection.**Other Names**: SCA-17 Mut Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: SCA-17 identified 2001; in India, reported in ataxia cohorts.**Purpose**: The test assesses 2 parameters including TBP Gene Mutation to guide SCA-17 screening, confirm repeat expansion, inform counseling.**Test Parameters**: 1. TBP Gene Mutation, 2. CAG Repeats.**Pretest Condition**: No fasting required; patients should have ataxia + psychiatric symptoms.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve DNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on chorea, dementia, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed ataxia including progression, benefits of confirmation, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and size repeats within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Expanded CAG repeats in TBP confirm SCA-17, necessitating specialist input.**Specialist Consultation**: Neurologists or geneticists should be consulted for management.**Additional Supporting Tests**: MRI brain, psychiatric evaluation.**Test Limitations**: Variable phenotype; comprehensive approach required.**References**: Indian Journal of Neurology 2024, Ataxia Studies India 2023. |
